ADVM Adverum Biotechnologies Inc.

+0.04  (+0%)
Previous Close 10.96
Open 10.98
Price To Book 3.73
Market Cap 701,588,415
Shares 63,780,765
Volume 532,003
Short Ratio
Av. Daily Volume 746,074

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Development to be discontinued - noted November 1, 2018.
Alpha-1 Antitrypsin (A1AT) Deficiency
Phase 2a negative data released June 2015 (met primary endpoint but increase in retinal thickness). As a result Phase 2b development will not proceed.
Wet age-related macular degeneration (Wet-AMD)
Phase 1 24-Week data from first cohort due 2H 2019. Partial clinical hold lifted on second cohort, May 16, 2019.
Wet age-related macular degeneration (Wet-AMD)

Latest News

  1. The Adverum Biotechnologies (NASDAQ:ADVM) Share Price Has Gained 252%, So Why Not Pay It Some Attention?
  2. Adverum Biotechnologies Doses First Patient in Second Cohort of OPTIC Phase 1 Clinical Trial of ADVM-022 Gene Therapy for Wet AMD
  3. Adverum Biotechnologies, Inc. (ADVM) Shares March Higher, Can It Continue?
  4. Biotech Stock Roundup: Label Expansion for CELG's Drugs, Setback for IMGN
  5. Adverum Up as FDA Lifts Hold on Cohort of Wet AMD Study
  6. 3 Biotech Stocks That Soared Last Week: Are They Buys?
  7. Tallgrass Energy
  8. All You Need to Know About Adverum Biotechnologies (ADVM) Rating Upgrade to Buy
  9. The Daily Biotech Pulse: Axovant Doses First Patient In Gene Therapy Trial, Agile Resubmits NDA, ADMA Prices Offering
  10. Adverum Biotechnologies Provides Update on OPTIC Phase 1 Trial for ADVM-022 in Wet AMD
  11. Tilray (TLRY) to Report Q1 Earnings: What's in the Cards?
  12. Adverum Biotechnologies (ADVM) Reports Q1 Loss, Lags Revenue Estimates
  13. Adverum Biotechnologies: 1Q Earnings Snapshot
  14. Adverum Biotechnologies Reports First Quarter 2019 Financial Results and Provides Corporate Update
  15. Evoke Pharma (EVOK) to Post Q1 Earnings: What's in Store?
  16. Adverum Biotechnologies Announces Board Changes
  17. Adverum Biotechnologies to Present 30-month Preclinical Safety and Expression Data for ADVM-022 Gene Therapy in Wet AMD at the ASGCT 22nd Annual Meeting
  18. Adverum Biotechnologies (ADVM) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
  19. Adverum Biotechnologies Presents First Preclinical Data on Dosing Contralateral Eye with ADVM-022 Gene Therapy for Wet AMD at the ARVO 2019 Annual Meeting
  20. Is a Beat in the Offing for Humana's (HUM) Q1 Earnings?